📊 CATX Key Takeaways
Investment Thesis
Perspective Therapeutics is a pre-revenue or early-stage biopharmaceutical company with severe operational losses and negative free cash flow of -$95.2M, indicating the business is burning substantial cash to fund R&D activities. With only $30.6M in cash reserves and annual cash burn exceeding $80M, the company faces critical runway constraints unless it secures additional financing or achieves clinical/commercial milestones imminently. The company's financial viability is highly dependent on successful drug development outcomes with uncertain probabilities, making this a speculative research-stage investment unsuitable for fundamental-based analysis.
CATX Strengths
- Strong liquidity position with current ratio of 5.17x and quick ratio of 5.14x providing near-term operational flexibility
- Low leverage with debt-to-equity ratio of 0.01x minimizing financial distress risk from debt obligations
- Substantial asset base of $267M with stockholders' equity of $207M providing capital reserves for development activities
CATX Risks
- Severe cash burn of -$95.2M in free cash flow with only 4-5 months of runway at current burn rates, requiring near-term financing
- Massive operating losses of -$113.6M on minimal $1.4M revenue indicating no commercial traction or path to profitability
- Typical biopharmaceutical development risk with 90%+ probability of clinical failure; financial sustainability entirely dependent on unproven drug candidates
Key Metrics to Watch
- Cash position and monthly burn rate; monitoring for dilutive financing or covenant violations
- Clinical trial progress and regulatory milestones for lead drug candidates affecting probability of eventual revenue
- Operating cash flow trend; any sustained improvement would indicate progress toward commercial viability
CATX Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 5.17x current ratio provides a solid financial cushion.
CATX Profitability Ratios
CATX vs Healthcare Sector
How Perspective Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
CATX Balance Sheet & Liquidity
CATX 5-Year Financial Trend
5-Year Trend Summary: Perspective Therapeutics, Inc.'s revenue has declined by 80% over the 5-year period, indicating business contraction. The most recent EPS of $-1.23 indicates the company is currently unprofitable.
CATX Growth Metrics (YoY)
CATX Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2023 | $1.7M | -$371.0K | $-0.03 |
| Q2 2023 | $1.5M | -$371.0K | $-0.01 |
| Q1 2023 | $1.7M | -$371.0K | $0.00 |
| Q3 2022 | $2.6M | -$713.0K | $-0.01 |
| Q2 2022 | $2.4M | -$713.0K | N/A |
| Q1 2022 | $2.4M | -$713.0K | N/A |
| Q3 2021 | $2.6M | -$545.0K | N/A |
| Q2 2021 | $2.2M | -$713.0K | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
CATX Capital Allocation
CATX SEC Filings
Access official SEC EDGAR filings for Perspective Therapeutics, Inc. (CIK: 0000728387)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CATX
What is the AI rating for CATX?
Perspective Therapeutics, Inc. (CATX) has an AI rating of STRONG SELL with 95% confidence, based on fundamental analysis of SEC EDGAR filings.
What are CATX's key strengths?
Strong liquidity position with current ratio of 5.17x and quick ratio of 5.14x providing near-term operational flexibility. Low leverage with debt-to-equity ratio of 0.01x minimizing financial distress risk from debt obligations.
What are the risks of investing in CATX?
Severe cash burn of -$95.2M in free cash flow with only 4-5 months of runway at current burn rates, requiring near-term financing. Massive operating losses of -$113.6M on minimal $1.4M revenue indicating no commercial traction or path to profitability.
What is CATX's revenue and growth?
Perspective Therapeutics, Inc. reported revenue of $1.4M.
Does CATX pay dividends?
Perspective Therapeutics, Inc. does not currently pay dividends.
Where can I find CATX SEC filings?
Official SEC filings for Perspective Therapeutics, Inc. (CIK: 0000728387) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CATX's EPS?
Perspective Therapeutics, Inc. has a diluted EPS of $-1.40.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.